SG11201806596TA - Pyridine derivative inhibiting raf kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof - Google Patents

Pyridine derivative inhibiting raf kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof

Info

Publication number
SG11201806596TA
SG11201806596TA SG11201806596TA SG11201806596TA SG11201806596TA SG 11201806596T A SG11201806596T A SG 11201806596TA SG 11201806596T A SG11201806596T A SG 11201806596TA SG 11201806596T A SG11201806596T A SG 11201806596TA SG 11201806596T A SG11201806596T A SG 11201806596TA
Authority
SG
Singapore
Prior art keywords
same
pyridine derivative
cancer
pharmaceutical composition
growth factor
Prior art date
Application number
SG11201806596TA
Inventor
Eui Hwan Cho
Hee Jong Shin
Min Hyo Ki
Ho Seok Kwon
Jae Woong Lee
Jeong Ho Joo
Keun Kuk Lee
Jong Min Kim
Yong Bin Park
Sung Hyun Kang
Hyoung Min Cho
Hyun Tae Kim
Soon Kil Ahn
Sung Pyo Hong
Sung Hye Kim
Original Assignee
Samjin Pharmaceutical Co Ltd
Univ Incheon Ind Acad Coop
Bamichem Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samjin Pharmaceutical Co Ltd, Univ Incheon Ind Acad Coop, Bamichem Co Ltd filed Critical Samjin Pharmaceutical Co Ltd
Publication of SG11201806596TA publication Critical patent/SG11201806596TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf, Raf-1, or B-RafV600E) and a vascular endothelial growth factor receptor (VEGFR2) involved in angiogenesis, and thus, can be favorably used for the prevention or treatment of melanoma, colorectal cancer, prostate cancer, thyroid 10 cancer, lung cancer, pancreatic cancer, ovarian cancer, or the like, which is induced by RAS mutation. 190
SG11201806596TA 2016-02-03 2017-01-11 Pyridine derivative inhibiting raf kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof SG11201806596TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160013643 2016-02-03
PCT/KR2017/000387 WO2017135589A1 (en) 2016-02-03 2017-01-11 Pyridine derivative inhibiting raf kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof

Publications (1)

Publication Number Publication Date
SG11201806596TA true SG11201806596TA (en) 2018-09-27

Family

ID=59499973

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806596TA SG11201806596TA (en) 2016-02-03 2017-01-11 Pyridine derivative inhibiting raf kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof

Country Status (13)

Country Link
US (1) US10844062B2 (en)
EP (1) EP3412670B1 (en)
JP (1) JP6768838B2 (en)
KR (1) KR102031033B1 (en)
CN (1) CN109071543B (en)
AU (1) AU2017215928A1 (en)
BR (1) BR112018015980A2 (en)
CA (1) CA3013569A1 (en)
CL (1) CL2018002095A1 (en)
PH (1) PH12018501645A1 (en)
RU (1) RU2018131437A (en)
SG (1) SG11201806596TA (en)
WO (1) WO2017135589A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102337870B1 (en) * 2020-02-03 2021-12-10 순천대학교 산학협력단 Substituted diarylurea compound for inducing apoptosis and composition for anticancer comprising the same
WO2022178256A1 (en) * 2021-02-18 2022-08-25 Black Diamond Therapeutics, Inc. 6-substituted-9h-purine derivatives and related uses
WO2023183444A1 (en) * 2022-03-24 2023-09-28 Vibliome Therapeutics, Llc Modulators of protein kinases
WO2023218245A1 (en) * 2022-05-13 2023-11-16 Voronoi Inc. Heteroaryl derivative compounds, and pharmaceutical composition comprising thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557830B2 (en) 2007-06-07 2013-10-15 Amgen Inc. RAF kinase modulators and methods of use
UY32582A (en) 2009-04-28 2010-11-30 Amgen Inc 3 KINASE PHOSPHINOSITI INHIBITORS AND / OR MAMMAL OBJECTIVE
CN103339132B (en) 2010-12-02 2017-02-15 株式会社麦迪帕克特 Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredi
KR101721739B1 (en) * 2011-11-14 2017-03-30 치아타이 티안큉 파마수티컬 그룹 주식회사 Kinase modulating compounds, compositions containing the same and use thereof
CN103102349B (en) * 2011-11-14 2017-03-15 北京赛林泰医药技术有限公司 Kinases inhibitor and combinations thereof and purposes
CN103387576A (en) * 2013-08-09 2013-11-13 中国药科大学 Aramide Raf kinase inhibitor based on purine structure and preparation method and application thereof

Also Published As

Publication number Publication date
AU2017215928A1 (en) 2018-08-23
EP3412670A4 (en) 2019-07-17
CA3013569A1 (en) 2017-08-10
EP3412670A1 (en) 2018-12-12
RU2018131437A (en) 2020-03-03
PH12018501645A1 (en) 2019-05-27
JP6768838B2 (en) 2020-10-14
KR102031033B1 (en) 2019-11-18
WO2017135589A9 (en) 2017-10-19
JP2019509334A (en) 2019-04-04
KR20170092453A (en) 2017-08-11
CN109071543B (en) 2021-07-16
EP3412670B1 (en) 2022-03-09
RU2018131437A3 (en) 2020-03-03
WO2017135589A1 (en) 2017-08-10
US10844062B2 (en) 2020-11-24
US20190300531A1 (en) 2019-10-03
CL2018002095A1 (en) 2019-01-11
BR112018015980A2 (en) 2018-12-18
CN109071543A (en) 2018-12-21

Similar Documents

Publication Publication Date Title
PH12018501645A1 (en) Pyridine derivative inhibiting raf kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof
ZA201807256B (en) Inhibitors of activin receptor-like kinase
MD4800B1 (en) Aminopyrimidinyl compounds as JAK inhibitors
PH12017500802B1 (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
PH12019501292A1 (en) Pharmaceutical composition for preventing or treating cancer, comprising tetraarsenic hexoxide crystalline polymorph
MX2019001125A (en) Macrocycle kinase inhibitors.
MX2019007243A (en) Ectonucleotidase inhibitors and methods of use thereof.
MX2019005526A (en) Bicyclic dihydropyrimidine-carboxamide derivatives as rho-kinase inhibitors.
MX2019006327A (en) Pharmaceutical composition for preventing or treating liver cancer, comprising tetraarsenic hexoxide crystalline polymorph.
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
MX2015014944A (en) 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1h-pyrrolo[2,3-c ]pyridine derivatives as nik inhibitors for the treatment of cancer.
MX2016016538A (en) Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors.
MX2015013419A (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors.
MY166210A (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
MX2016009581A (en) 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use.
MX2020003126A (en) Cyclic iminopyrimidine derivatives as kinase inhibitors.
PH12019501873A1 (en) Pharmaceutical composition
MX2016009621A (en) Furo-3-carboxamide derivatives and methods of use.
MX369473B (en) Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising same and use thereof.
PH12017502081A1 (en) Composition, containing quisqualis indica extract, for preventing or treating prostatic hyperplasia
PH12019501252A1 (en) Compositions and methods related to pyridinoylpiperidine 5-htif agonists
MX2015012343A (en) Substituted pyridine derivatives useful as c-fms kinase inhibitors.
MX2017014752A (en) Novel amidoheteroaryl aroyl hydrazide ethynes.
NZ738247A (en) 4-(3-pyrazolylamino)-benzimidazole compounds and their use as jak1 inhibitors
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds